Did anyone write down the breakdown of what percent of the Valor trial was in US, Europe, Aus/NZ?
They broke it down at the Stifel Nicoloas conference but I didn't write it down and now the webcast has been removed. I kept thinking 60% in US with 40% of them from MD Anderson?? 75% of the European studies were in GB, France, Germany? If anyone jotted this info, I would be very appreciative.
Sorry about bad info on the L-1 Monotherapy study that I posted. My research showed that even though we might not hit a remission rate of 30% that we would have a meaningful rate to move on to the next phase. Very disappointing. As Dan said today, the thought is that the facilities sponsoring the trial did not have the appropriate understanding and care to see patients through the sepsis, anemia, etc, which often occurs as bone marrow suppressed. Bridging to transplant is the key for OS IMO. Like I said, sorry for the misinformation. Obvious renewed interest in the stock yesterday and today. I don't know if this is instos or if this directors/management exercising options, etc in the small window before end of quarter that is not blacked out. We will find out if management with SEC file 4's in next few days. If no releases then someone taking on a larger position. I still have strong faith that we see a 20-25% increase in Overall Survival conservatively. 25% will certainly move the needle and we move forward. 20% with high hazard ratio is a little harder to figure out how WS reacts.
Enough babbling, anyone got the breakdown by continent would be wonderful and very much appreciated. Expect fairly flat trading range in next 3 months. GLTA longs.